Budget impact analysis of treatment‐free remission in nilotinib‐treated Japanese chronic myeloid leukemia patients. Issue 7 (23rd May 2020)

• Record Type: Journal Article
• Authors: Yamazaki, Kiyotaka; Inagaki, Naohito; Moldaver, Daniel; Viana, Ricardo; Kimura, Shinya
• Is Part Of: Cancer science. Volume 111:Issue 7(2020)
• Page Start: 2526
• Page End: 2535
• Publication Date: 2020-05-23
• Subjects: budget impact -- chronic myeloid leukemia -- molecular monitoring -- nilotinib -- treatment‐free remission; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.14430
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract: Treatment‐free remission (TFR), in which patients discontinue pharmacotherapy and remain in molecular remission, is an emerging treatment goal for patients with chronic myeloid leukemia (CML). Attainment of TFR requires an increased frequency of molecular monitoring, to ensure that patients maintain a deep molecular response. The objective of this analysis was to assess the economic impact of stopping nilotinib among Japanese TFR‐eligible patients. A Markov model evaluated the economic impact of TFR among the study population, TFR‐eligible CML patients diagnosed since 2012. The model compared patients who had discontinued tyrosine kinase inhibitor (TKI) treatment (ie, attempted TFR) with patients that continued TKI treatment. A 3‐y time horizon was modeled from a Japanese public payer perspective. Costs associated with drug treatment, hospital/physician visits, and molecular monitoring were considered. TFR‐eligible patients were calculated from Japanese CML incidence rates and efficacy was derived from nilotinib trials. Japanese co‐payment maximums were utilized to assess the patient perspective. An estimated 761 and 140 patients were eligible for first‐ and second‐line nilotinib, respectively, in 2019. Assuming that 100% of eligible patients complied, TFR was associated with cost savings of ¥7 625 174 640 (US$66 567 775) over 3 y. In scenarios with reduced willingness to attempt TFR, cost savings persisted. Achievement of TFR was estimated to markedly reduce out‐of‐pocket expenses for CML patients, regardless of the timing of relapse. Stopping nilotinib for TFR‐eligible patients in Japan may result in significant cost savings to both payers and patients. Monitoring costs contributed little to overall annual costs and decreased over time. Abstract : The budget impact analysis of treatment‐free remission (TFR) in TFR‐eligible patients in Japan identified marked cost savings. It was estimated that nilotinib discontinuation in all TFR‐eligible Japanese CML patients would yield incremental savings of ¥7 625 174 640 (US$66 567 775) over 3 y, compared with continued TKI treatment.